10-Q: Biomerica Reports Net Sales Increase but Faces Going Concern Uncertainty in Q3 2025

Sentiment:

Quarterly Report 14 April 2025 4:15 PM

Biomerica, Inc. reports a net sales increase of 6% for the nine months ended February 28, 2025, but acknowledges substantial doubt about its ability to continue as a going concern due to insufficient cash and strategic growth objectives.

Capital raiseThe company has a shelf registration statement on Form S-3 with the SEC, allowing it to issue up to $20,000,000 in common shares.The company filed a prospectus supplement with the SEC to facilitate the sale of up to $5,500,000 in common stock through at-the-market (ATM) offerings.During the nine months ended February 28, 2025, the company sold 3,525,359 shares of its common stock at prices ranging from $0.36 to $1.04 pursuant to the May 2024 ATM Offering, which resulted in net proceeds of approximately $2,015,000.

Worse than expectedThe company expresses substantial doubt about its ability to continue as a going concern.The company's current cash and cash equivalents are insufficient to meet operating cash requirements and strategic growth objectives for the next twelve months.

Summary

Biomerica, Inc. reported its financial results for the third quarter of fiscal year 2025, ended February 28, 2025.
Net sales for the three months ended February 28, 2025, increased by 10% to $1,119,000 compared to $1,017,000 for the same period in 2024.
The increase in sales was primarily driven by increased sales of food intolerance products.
Cost of sales decreased by 6% to $1,100,000 for the three months ended February 28, 2025, compared to $1,166,000 for the same period in 2024.
Selling, general, and administrative expenses decreased by 33% to $1,012,000 for the three months ended February 28, 2025, compared to $1,508,000 for the same period in 2024.
Research and development expenses decreased by 37% to $217,000 for the three months ended February 28, 2025, compared to $343,000 for the same period in 2024.
Interest and dividend income decreased by 50% to $43,000 for the three months ended February 28, 2025, compared to $86,000 for the same period in 2024.
Net sales for the nine months ended February 28, 2025, increased by 6% to $4,562,000 compared to $4,299,000 for the same period in 2024.
The increase in sales was largely driven by enhanced contract manufacturing billings and increased demand for the inFoods IBS product.
Cost of sales increased by 3% to $3,820,000 for the nine months ended February 28, 2025, compared to $3,708,000 for the same period in 2024.
Selling, general, and administrative expenses decreased by 16% to $3,544,000 for the nine months ended February 28, 2025, compared to $4,204,000 for the same period in 2024.
Research and development expenses decreased by 37% to $771,000 for the nine months ended February 28, 2025, compared to $1,226,000 for the same period in 2024.
Interest and dividend income decreased by 56% to $140,000 for the nine months ended February 28, 2025, compared to $317,000 for the same period in 2024.
The company has an accumulated deficit of approximately $52 million as of February 28, 2025.
The company had cash and cash equivalents of approximately $3,058,000 and working capital of approximately $4,555,000 as of February 28, 2025.
The company sold 3,525,359 shares of its common stock at prices ranging from $0.36 to $1.04 pursuant to the May 2024 ATM Offering, which resulted in net proceeds of approximately $2,015,000.
Management believes that current cash and cash equivalents are insufficient to meet operating cash requirements and strategic growth objectives for the next twelve months.
The company is actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity, and seek other strategic alternatives.
These factors raise substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as increased net sales and reduced expenses, the going concern warning and reliance on ATM offerings raise significant concerns about the company's financial stability. The sentiment is therefore cautiously negative.

Positives

Net sales increased by 10% for the three months ended February 28, 2025, and 6% for the nine months ended February 28, 2025.
Selling, general, and administrative expenses decreased by 33% for the three months ended February 28, 2025, and 16% for the nine months ended February 28, 2025.
Research and development expenses decreased by 37% for both the three and nine months ended February 28, 2025.
The company raised $2,015,000 in net proceeds from the May 2024 ATM offering.
The company's current quarterly cash burn has improved to approximately $800,000 compared to approximately $1,800,000 in the same period of last year.

Negatives

Management expresses substantial doubt about the company's ability to continue as a going concern.
The company has an accumulated deficit of approximately $52 million as of February 28, 2025.
Interest and dividend income decreased by 50% for the three months ended February 28, 2025, and 56% for the nine months ended February 28, 2025.
The company's current cash and cash equivalents are insufficient to meet operating cash requirements and strategic growth objectives for the next twelve months.

Risks

The company's ability to continue as a going concern is uncertain.
The company's ability to generate additional revenue from international opportunities and new product launches is uncertain.
The company's ability to access the capital and debt markets to meet current obligations and fund operations is uncertain.
The company's ability to retain key employees and maintain critical operations with a substantially reduced workforce is a risk.
SEC regulations limit the amount of capital the company can raise through issuance of its equity.

Future Outlook

Management believes that current cash and cash equivalents are insufficient to meet operating cash requirements and strategic growth objectives for the next twelve months and is actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity, and seek other strategic alternatives.

Management Comments

Feedback from GI specialists has been generally positive, and we are continuing to expand our network by onboarding additional physician practices.
These efforts are intended to lay the groundwork for broader adoption by showcasing the distinct clinical value of inFoods across multiple healthcare channels.
Due to the slower-than-expected launch of the Company's key products, inFoods IBS and hp+detect, the Company has executed significant cost-cutting measures to extend its cash runway and work towards increasing revenues to cover overhead costs.

Industry Context

The company operates in the global biomedical technology industry, focusing on diagnostic and therapeutic products. The industry is characterized by technological advances, increasing demand for point-of-care diagnostics, and a growing focus on personalized medicine. Biomerica's focus on gastrointestinal diseases and food intolerances aligns with the increasing prevalence of these conditions and the growing demand for effective diagnostic and treatment solutions.

Comparison to Industry Standards

It's difficult to provide a direct comparison to industry standards without specific competitor data.
However, Biomerica's focus on point-of-care diagnostics aligns with a broader industry trend.
Companies like QuidelOrtho and Abbott are major players in the diagnostics market, but their product portfolios and financial scales are significantly larger than Biomerica's.
Biomerica's reliance on ATM offerings for financing is not uncommon for smaller companies in the biotech sector, but it also highlights the challenges they face in securing more traditional funding sources.
The company's cost-cutting measures and strategic focus on key products are consistent with efforts by other small-cap companies to navigate challenging market conditions.

Stakeholder Impact

Shareholders face the risk of dilution from ATM offerings and potential loss of investment if the company cannot continue as a going concern.
Employees may face further workforce reductions if cost-cutting measures continue.
Customers may be affected by the company's ability to continue providing products and services.
Suppliers may be affected by the company's ability to pay its obligations.

Next Steps

The company intends to use the net proceeds from the ATM offering for general corporate purposes, including sales and marketing activities, clinical studies and product development, acquisitions of assets, businesses, companies, or securities, capital expenditures, and working capital needs.
The company is actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity, and seek other strategic alternatives.

Key Dates

Date	Description
2016-11-01	Date of a lease for manufacturing space entered into by Biomerica de Mexico.
2020-07-21	Filing date of Form S-3 shelf registration statement with the SEC.
2020-09-30	SEC declared the Form S-3 shelf registration statement effective.
2021-01-22	Filing date of prospectus supplement for at-the-market offerings.
2023-03-07	Date of firm commitment public offering of common stock.
2023-06-01	Adoption of Accounting Standards Update (ASU) No. 2016-13, Financial Instruments – Credit Losses (codified as Accounting Standards Codification (ASC) 326).
2023-09-28	Filing date of new shelf registration statement on Form S-3 with the SEC.
2023-09-29	SEC declared the new shelf registration statement on Form S-3 effective.
2024-05-10	Filing date of prospectus supplement with the SEC to facilitate the sale of up to $5,500,000 in common stock through ATM offerings.
2024-05-31	End of fiscal year 2024.
2024-08-28	Filing date of the Company's Annual Report on Form 10-K with the SEC.
2025-02-28	End of the quarterly period covered by the report.
2025-04-14	Date of the report.

Keywords

financial results, net sales, Biomerica, ATM offering, going concern, expenses, revenue, liquidity

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.